Literature DB >> 19033875

Efficacy of anakinra in a case of refractory Still disease.

Severine Debiais1, Francois Maillot, Luminita Luca, Jennifer Buret, Bruno Fautrel, Jean Paul Renard.   

Abstract

Mesh:

Substances:

Year:  2008        PMID: 19033875     DOI: 10.1097/RHU.0b013e318188b8d8

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


× No keyword cloud information.
  6 in total

Review 1.  Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.

Authors:  R Goldbach-Mansky
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

2.  May anakinra be used earlier in adult onset Still disease?

Authors:  Guillaume Moulis; Laurent Sailler; Leonardo Astudillo; Gregory Pugnet; Philippe Arlet
Journal:  Clin Rheumatol       Date:  2010-04-30       Impact factor: 2.980

Review 3.  Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome.

Authors:  Pierre Quartier
Journal:  Open Access Rheumatol       Date:  2011-01-18

4.  Epidemiology and outcome of articular complications in adult onset Still's disease.

Authors:  Madiha Mahfoudhi; Rafik Shimi; Sami Turki; Adel Kheder
Journal:  Pan Afr Med J       Date:  2015-09-30

Review 5.  Biological therapy of traditional therapy-resistant adult-onset Still's disease: an evidence-based review.

Authors:  Sha Zhou; Jianjun Qiao; Juan Bai; Yinhua Wu; Hong Fang
Journal:  Ther Clin Risk Manag       Date:  2018-01-24       Impact factor: 2.423

6.  Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.

Authors:  Serena Colafrancesco; Maria Manara; Alessandra Bortoluzzi; Teodora Serban; Gerolamo Bianchi; Luca Cantarini; Francesco Ciccia; Lorenzo Dagna; Marcello Govoni; Carlomaurizio Montecucco; Roberta Priori; Angelo Ravelli; Paolo Sfriso; Luigi Sinigaglia
Journal:  Arthritis Res Ther       Date:  2019-12-11       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.